Advancing Precision
Medicine
From Biomarker
to CDx

Oncologists already use clinical features like race and smoking status to manage decision-making when treatment delays pending molecular results are likely to be appropriate. I would definitely use a science-forward, reliable, and ultra-rapid AI test to enhance this process in supporting an informed clinical decision.

Imagene’s AI-based biomarker detection shows great promise for significantly reducing the waiting time for patients to begin targeted therapies.
This kind of technology can lead to better and earlier cancer care for patients no matter where they live.

The ability to use Imagene’s AI technology under research is a game-changer. It allowed us to bypass the usual lengthy waiting period associated with comprehensive genomic profiling. This technology is revolutionizing the way we diagnose patients, with the potential to improve outcomes and save lives.

Tempus is committed to broadly offering AI-enabled diagnostics in an effort to improve patient outcomes. This collaboration with Imagene strengthens our diagnostic offerings and allows us to provide clinicians more actionable data that may lead to additional testing.

CanvOI transforms our approach to healthcare and disease understanding. By providing access to comprehensive oncology intelligence in the cloud, it enables researchers to develop answers quicker and more efficiently. This technology marks a new era of cancer research that pushes us closer to a future where cancer is a manageable condition.

Cancer continues to have a devastating impact on individuals and families, but with advancements in cloud and AI we have an opportunity to help change this narrative. We are proud to be working with companies like Imagene AI to support breakthroughs in oncology that can help improve outcomes for those afflicted with this disease.